- Home
- PRAX vs OPY Comparison
PRAX vs OPY Comparison
Compare PRAX & OPY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- OPY
- Stock Information
- Founded
- PRAX 2015
- OPY 1881
- Country
- PRAX United States
- OPY United States
- Employees
- PRAX N/A
- OPY N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- OPY Investment Bankers/Brokers/Service
- Sector
- PRAX Health Care
- OPY Finance
- Exchange
- PRAX Nasdaq
- OPY Nasdaq
- Market Cap
- PRAX 950.8M
- OPY 766.7M
- IPO Year
- PRAX 2020
- OPY N/A
- Fundamental
- Price
- PRAX $46.85
- OPY $72.66
- Analyst Decision
- PRAX Strong Buy
- OPY
- Analyst Count
- PRAX 9
- OPY 0
- Target Price
- PRAX $94.44
- OPY N/A
- AVG Volume (30 Days)
- PRAX 388.4K
- OPY 34.3K
- Earning Date
- PRAX 08-04-2025
- OPY 10-24-2025
- Dividend Yield
- PRAX N/A
- OPY 0.99%
- EPS Growth
- PRAX N/A
- OPY 41.03
- EPS
- PRAX N/A
- OPY 7.71
- Revenue
- PRAX $7,765,000.00
- OPY $1,400,370,000.00
- Revenue This Year
- PRAX N/A
- OPY N/A
- Revenue Next Year
- PRAX $25.00
- OPY N/A
- P/E Ratio
- PRAX N/A
- OPY $9.66
- Revenue Growth
- PRAX 338.45
- OPY 14.40
- 52 Week Low
- PRAX $26.70
- OPY $47.39
- 52 Week High
- PRAX $91.83
- OPY $77.83
- Technical
- Relative Strength Index (RSI)
- PRAX 47.63
- OPY 53.36
- Support Level
- PRAX $44.13
- OPY $69.59
- Resistance Level
- PRAX $47.06
- OPY $75.00
- Average True Range (ATR)
- PRAX 2.18
- OPY 1.64
- MACD
- PRAX 0.05
- OPY 0.09
- Stochastic Oscillator
- PRAX 54.73
- OPY 59.79
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About OPY Oppenheimer Holdings Inc. (DE)
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has two segments: Wealth Management, and Capital Markets. IT generates maximum revenue from Wealth Management Segment which includes commissions and fee income earned on assets under management (AUM), net interest earnings on client margin loans and cash balances, fees from money market funds, custodian fees and other activities. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.